[{"from": "human", "value": "Describe this molecule. [C][C][C][N][C@@H1][Branch1][Ring2][C][Ring1][=Branch1][C][Branch2][Ring2][O][C][N][Branch1][Ring2][C][Ring1][Ring2][C][=Branch1][C][=O][C][=C][Branch1][=N][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][F][N][C][=C][Branch1][#Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][I][F][O]"}, {"from": "gpt", "value": "The molecule is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma."}]